Addressing gene therapy translational R&D bottlenecks in the CNS

Cell & Gene Therapy Insights 2023; 9(1), 181–185

DOI: 10.18609/cgti.2023.026

Published: 9 March 2023
Anindya Sen

Anindya Sen

Executive Director, R&D, Prevail Therapeutics

“Two major current bottlenecks in central nervous system (CNS)-directed gene therapy are finding the right capsid and identifying the right route of administration.”

On February 2nd 2023, David McCall, Editor, Cell & Gene Therapy Insights, spoke to Anindya Sen, Executive Director, R&D at Prevail Therapeutics, about novel AAV capsid innovation and preclinical-clinical translation challenges in the CNS gene therapy space. This viewpoint has been written based on that interview.